
    
      Adult patients with advanced Non-small Cell Lung Cancer (NSCLC) and nonprogression after
      platinum-based chemotherapy will be randomized 1:1 to receive either OSI-906 plus erlotinib
      or placebo plus erlotinib.
    
  